Rebecca Leary, Novartis, to Present at 2nd Cancer Markers & Liquid Biopsies

Rebecca Leary, Novartis, to Present at 2nd Cancer Markers & Liquid Biopsies

Online PR News – 27-April-2016 – Boston – Rebecca Leary, Research Investigator III, Oncology Research at Novartis Institutes for Biomedical Research, will give a presentation on, “Characterizing the Cancer Genome from the Circulation” at GTCbio’s 2nd Cancer Markers & Liquid Biopsies Conference to be held on July 6-7, 2016 in Boston, MA.

Circulating tumor DNA (ctDNA) provides an opportunity for non-invasive assessment of tumor genotype, and may enable rational use of targeted therapies at multiple clinical milestones. Implementation of ctDNA-based assays across clinical and research settings highlights important assay characteristics and suggests future clinical applications.

Leaders in industry and academia will discuss platforms for isolating and studying CTCs. Technologies such as next generation sequencing and digital PCR are gaining momentum in these research areas. Biomarker sensitivity, stability, validation, and how we can use markers to follow up with patients and improve the quality of life, will also be discussed.

Session Topics:
I. Isolation, Characterization & Diagnostic Applications of CTCs
II. Advances in the Clinical Application of Circulating Nucleic Acids
III. Validation & Application of Cancer Specific Markers
IV. Current Progress in Exosome Application
V. Clinical & Biological Challenges in Liquid Biopsy

This conference is also part of our larger Molecular Diagnostics Summit, which includes two additional conferences:
2nd Cancer Markers & Liquid Biopsies
Precision Medicine
Digital PCR & qPCR

For more information, please visit website:

635 W. Foothill Blvd
Monrovia, CA 91016
Phone: (626) 256-6405
Fax: (626) 466-4433